anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Guangdong Provincial People's Hospital will be the lead center, with an additional 4 hospitals designated as satellite centers for the study. Enrollment of up to 500 participants adults aged over 18 years hospitalized for ADHF is planned, with a minimum of of 195 cases each for patients with and without sarcopenia The sympathetic nervous activity, psychosocial factors, quality of life, physical function and baseline physical activity will also be observed and recorded at baseline. Each patient is followed up for 6 month, 1 year, 2 years or until the occurrence of death. The primary clinical outcome is all-cause mortality at 6 months. Other clinical outcomes of interest include cardiovascular mortality, all-cause hospitalisation, HF hospitalisation, the frequency and length of hospitalization of patient readmitted and survival time from enrollment to death of deceased patients.

This study will examine the correlation between sarcopenia and prognosis in different subgroups of patients, and explore the additive effect of different comorbidities and sarcopenia on prognosis in patients with acute decompensated heart failure. S-ADHF will provide important information and evidence on the clinical aspects of sarcopenia in patients with ADHF, and will potentially and contribute to accurate risk stratification and optimal clinical management for patient with ADHF.
FIELD: medicine, more particularly, cleaning of plasma proteins from lipoproteins. SUBSTANCE: proteins are cleaned by treatment with chloroform in the presence of EDTA-Na or EDTA or buffers containing borate ions, succinate ions, nitrate ions and subsequent addition of calcium or magnesium salts to remove precipitate by centrifugation. In addition to 2- step removal of lipoproteins, also described is single- step variant of method which comprises treating plasma proteins with chloroform and subsequently adding soluble calcium or magnesium salts. The resulting precipitate is removed by centrifugation. EFFECT: higher degree of delipidization and higher yield. 7 cl, 4 ex, 1 tbl
Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccine administration. In this arm, participants will receive a standard vaccine dose (5.5x10\^4 Plaque Forming Units) of YFV-17D administered subcutaneously in the right deltoid and placebo vaccination transcutaneously (then covered with a semi-occlusive dressing) in the left deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administer assigned treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
Sleeping in a standard bed and "flat" (\<30 degrees from supine position) position for 4 weeks. Patients can define their own most comfortable position during the night.
The study proposed is of immense importance in directing future methodology for bringing children who have not received needed immunizations up to date. The proposed study builds on the success of a previous trial and incorporates data from providers and patients to further improve the intervention. In this study the investigators aim to increase the effectiveness, cost effectiveness, and acceptability to practices and families of population-based R/R by introducing a strong private-public collaboration and maximizing health information technologies that allow practices to interface with Colorado's Immunization Services System (CIIS). Two real-world approaches will be compared: one approach will provide primary care practices the tools to conduct recall and educational interventions. In the other approach, population-based centralized recall by the state immunization registry will be conducted in collaboration with practices. Determining which of these methods is most effective in reaching the most children and comparing the cost of each will provide data critical in guiding future national efforts to assure that children entering school are fully vaccinated. Because the trial will be conducted at the level of both urban and rural counties throughout the state and will include all types of providers, the investigators expect our findings to be nationally generalizable.
In recent decades, due to insufficient concentration at the lesion site, low bioavailability and increasingly serious resistance, antibiotics have become less and less dominant in the treatment of bacterial infectious diseases. It promotes the development of efficient drug delivery systems, and is expected to achieve high absorption, targeted drug release and satisfactory therapy effects. A variety of endogenous stimulation-responsive nanosystems have been constructed by using special infection microenvironments (pH, enzymes, temperature, etc.). In this review, we firstly provide an extensive review of the current research progress in antibiotic treatment dilemmas and drug delivery systems. Then, the mechanism of microenvironment characteristics of bacterial infected lesions was elucidated to provide a strong theoretical basis for bacteria-targeting nanosystems design. In particular, the discussion focuses on the design principles of single-stimulus and dual-stimulus responsive nanosystems, as well as the use of endogenous stimulus-responsive nanosystems to deliver antimicrobial agents to target locations for combating bacterial infectious diseases. Finally, the challenges and prospects of endogenous stimulus-responsive nanosystems were summarized.
Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 courses in the absence of disease progression or unacceptable toxicity.
Qualitative interviews regarding the impact of COVID-19 will be conducted with youth who have an eating disorder (ED), parents of youth who have an ED, ED clinicians and ED program administrators, as well as get their perspectives on parent-led peer support groups. Three parent-led peer support groups will be started, including psychoeducation in a virtual group setting for parents who have a child or adolescent with an eating disorder.
(See WARNINGS)

For induction therapy in adult patients with AML the following dose schedule is recommended:

IDAMYCIN PFS Injection 12 mg/m2 daily for 3 days by slow (10 to 15 min) intravenous injection in combination with cytarabine. The cytarabine may be given as 100 mg/m2 daily by continuous infusion for 7 days or as cytarabine 25 mg/m2 intravenous bolus followed by cytarabine 200 mg/m2 daily for 5 days continuous infusion. In patients with unequivocal evidence of leukemia after the first induction course, a second course may be administered. Administration of the second course should be delayed in patients who experience severe mucositis, until recovery from this toxicity has occurred, and a dose reduction of 25% is recommended. In patients with hepatic and/or renal impairment, a dose reduction of IDAMYCIN PFS should be considered. IDAMYCIN PFS should not be administered if the bilirubin level exceeds 5 mg%. (See WARNINGS.)

The benefit of consolidation in prolonging the duration of remissions and survival is not proven. There is no consensus regarding optional regimens to be used for consolidation. (See CLINICAL STUDIES for doses used in U.S. Clinical studies.)
FIELD: medicine, immunology. SUBSTANCE: invention proposes a vaccine for prophylaxis and treatment of patients with T-cells mediated pathology or nonregulated replication of mammals T-cells that contains an active substance and pharmaceutically tolerantable medium. It has receptor of T-cells or its fragment corresponding to T-cells receptor as an active substance and located on surface mediating this pathology or anti-idiotypic antibodies that are an internal image of this receptor or its mentioned fragment. An active substance is taken at immunogenic effective amount. Vaccine is prepared by preparing T-cell clones causing T-cells mediated pathology and involves the determination of amino acid sequence of receptors of T-cells of clones of T-cells associated with this pathology, selection of fragments of these T-cell receptors which are typical for mentioned receptors of T-cells rather then for receptors of T-cells not associated with this pathology. Then method involves the selection of nonmentioned sequences that are able to induction of immunogenic response with respect to mentioned T-cells receptors that results to the vaccine selection. Also, invention proposes a method of diagnosis or prognosis of the person susceptibility to rheumatoid arthritis that involves the detection of T-cells containing variable site of β-strand: MSNQVLCCVVLCFLGANTVDGGITQSPKYLFRKQNVTLSCEQNLNDAMYWYRQDPGQGLRL- -IYYSQIVNDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASS or its fragment in the person sample. Anomalous expression of T-cells containing this site indicates the presence of rheumatoid arthritis or susceptibility to rheumatoid arthritis and a method of prophylaxis and treatment of patients with rheumatoid arthritis. Method involves the prevention of binding T-cells receptor containing the sequence: MSNQVLCCVVLCFLGANTVDGGITQSP- -KYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLLIYYSQIVNDFQKGDIAEGYSVS- -REKKESFPLTVTSAQKNPTAFYLCASS or T-cells receptor containing mainly the sequence SGDQGGNE with its partner and a method of prophylaxis and treatment of patients with rheumatoid arthritis. Method involves cytotoxic or cytostatic treatment of T-cells, the sequence MSNQVLCCVVLCFLGANTVDGGITQSPKYLFRKEGQNVTLSCEQNLNH- -DAMYWYRQDPGQGLRLIYYSQIVNDFQKGDIAEGYSVSPEKKESFPLTVTSAQKNPTAFY- -CASS or T-cells containing mainly the sequence SGDGGNE in the person. EFFECT: vaccine indicated above, improved method of prophylaxis and treatment, active peptide. 21 cl, 10 tbl, 9 ex
PRCIS: An objective perimetry method provides four 30-2 style reports in 8 minutes. These comprise sensitivity and delay reports for both eyes. A combined report format shows comparable diagnostic power to 2 forms of automated perimetry.
PURPOSE: To compare objective perimetry with 2 forms of standard automated perimetry (SAP) in glaucoma.
METHODS: The study cohort contained 40 persons with glaucoma (PwG) and 94 normal control subjects. The PwG had both perimetric and preperimetric eyes. Multifocal pupillographic objective perimetry was performed with the objectiveField Analyser (OFA), which independently assesses the visual fields of both eyes concurrently. Its OFA30 test assessed the central ±30 degrees, and the OFA15 test assessed the central ±15 degrees, both providing 30-2 style reports. The OFA tests were repeated 2 weeks apart to assess test-retest variability (TRV). OFA was compared with Matrix and HFA-SITA fast 24-2 threshold testing. Diagnostic power was quantified as the area under the receiver operating characteristic curves (AUROC). Test durations, mean defects, and pattern standard deviations of the 4 tests were compared.
RESULTS: At a median of 4.09±0.02 minutes/eye the OFA tests were quicker than SAP (all P ≤0.0001), 2 minutes/eye if OFA per-region sensitivities and delays are considered separately. The %AUROCs for OFA, Matrix, and HFA were not significantly different, averaging 93±3% (mean±SD) in perimetric eyes, and 73±6% in preperimetric eyes. For moderate to severe fields, OFA TRV was less than the published results for SAP. OFA30 mean defects were significantly correlated between repeats ( r =0.91) and with OFA15 ( r =0.93, both P <0.0001).
CONCLUSIONS: OFA provides extra functional measures in the form of per-region delays and between-eye asymmetries. Both the OFA wide-field and macular tests provided comparable diagnostic power to SAP and better TRV in damaged eyes.
Intradetrusor injection of onabotulinumtoxinA, which is performed thorough a cystoscopic procedure, has been demonstrated to be efficacious in the treatment of both neurogenic and non-neurogenic overactive bladder (OAB), and is FDA approved as a treatment for OAB. Intradetrusor of onabotulinumtoxinA is currently standard of care in patients with persistent OAB symptoms despite behavioral therapies and oral medication treatments for OAB. As one of the main adverse events associated with intradetrusor injection of onabotulinumtoxinA is UTI, and published guidelines for cystoscopic procedures with manipulation recommend the use of prophylactic antibiotics, a single dose of prophylactic antibiotic is administered prior to this procedure as the current standard of care. However, the guideline recommendations are primarily based on data from randomized controlled trials (RCTs) involving antimicrobial prophylaxis during transurethral resection of the prostate, and does not address cystoscopic injection procedures like onabotulinumtoxinA injection. Studies have reported that up to 50% of antibiotic usage is inappropriate, leading to unnecessary exposure of patients to potential complications of antibiotic therapy, including Clostridium difficile infection which can cause recurrent diarrhea that may progress to sepsis and death, increasing antibiotic resistances, as well as dermal/allergic and gastro-intestinal manifestations. In an effort to optimize antibiotic usage, antimicrobial stewardship is required in nursing facilities, acute-care and critical care hospitals, as well as ambulatory care centers. These efforts highlight the importance of re-evaluating our current practice standard of prophylactic antibiotic administration in urologic procedures. A prospective study that included patients undergoing intradetrusor onabutulinumtoxin injections who were not symptomatic for UTI and did not receive antibiotic prophylaxis demonstrated that the rate of post-procedure UTI within 6 weeks of treatment was not significantly different in those with a sterile urine culture compared to those with asymptomatic bacteriuria, suggesting that in patients who are not symptomatic for UTI, antibiotic prophylaxis may not be necessary prior to intradetrusor onabotulinumtoxin injection. To date, there have been no randomized studies that evaluate differences in outcomes when prophylactic antibiotics are not given prior to onabotulinumtoxinA injection. Therefore, in an effort to optimize antibiotic use, the investigators propose a prospective, randomized study to formally investigate whether there is a difference in the rate of symptomatic post-procedure UTI after intradetrusor onabotulinumtoxin when antibiotic prophylaxis is given compared to when antibiotic prophylaxis is not given in patients who are not symptomatic for UTI and have a negative urinalysis. The proposed study seeks to evaluate the current practice standard of antibiotic prophylaxis prior to intradetrusor onabotulinumtoxin injection.
Participants in this group will receive a standard care dietary plan. They will also be asked to gradually increase their activity up to 300 min/week by 6 months.
Patients assigned to this arm will receive Acceptation and Commitment Therapy (ACT) in groups of 8-12 patients. Intervention has been protocolized. Therapy will be administered by two experienced therapists (psychologists).
NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time. Exemplary pharmaceutical compositions include compositions including glibenclamide and memantine; glibenclamide and donepezil; tolbutamide and memantine; tolbutamide and donepezil; and these compositions further including glucagon and/or glucose.
Disclosed herein is a medicine composition for facilitating treating organs of a mammal, in accordance with some embodiments. Accordingly, the medicine composition may include carbanions and a diluting agent. Further, a carbanion of the carbanions may include a carbon atom. Further, the carbon atom may include a formal charge of −1. Further, the diluting agent may be capable of combining with the carbanions for forming at least one appliable form of the medicine composition. Further, a ratio of the diluting agent to the carbanions by volume ranges from 512:1 to 32:1. Further, the combining facilitates applying of the at least one appliable form of the medicine composition to at least one organ of the mammal.
The present invention relates to systems and methods for providing value added services. a request for a service for a recipient is received. A value added service may then be matched to the recipient. These value added services are vetted beforehand. The matching takes into account the recipients limitations, including physical and mental limitations, and location, and the value added service rating. The recipient's limitations; and the matching include optimizing the value added service to the profile of the recipient. The profile includes likes and dislikes of the recipient. Lastly, approval of the value added service is received from the recipient and/or the friends of family of the recipient.
1,165,198. Dentifrice compositions; polishing and abrasive agents. FARBWERKE HOECHST A.G. 16 Dec., 1966 [17 Dec., 1965], No. 56446/66. Heading A5B. Dentifrice compositions containing a fluoride, contain a mixture of magnesium ammonium phosphate and calcium hydrogen phosphate as a polishing and abrasive agent. The fluoride may be that of an alkaline earth metal, e.g. magnesium, or an alkali metal, e.g. potassium or sodium, or a mixture or double salt thereof. The polishing agent salts are preferably present as hydrates, i.e. the hexahydrate of the Mg salt and the dihydrate of the Ca salt. Other ingredients mentioned are humectants, e.g. glycenol, sorbitol or urea; binders, e.g. carboxymethyl cellulose, tragacanth or agar; surface active or foaming agents, e.g. lauryl sulphate; flavouring and sweetening agents and preservatives; also unspecified antiseptics, bleaches, astringents, deodourizing and anticareous agents may be present. The compositions may take the form of tooth powders, tooth soaps, or tooth-pastes. The polishing agents used are said not to combine with or adsorb fluoride ions. A comparative Example is included for a composition lacking magnesium ammonium phosphate.
Spastic elbow deformity in patients with upper motor neuron injuries results from an imbalance of flexor and extensor forces across the ulnohumeral joint. Although not all deformities reflect the same underlying imbalances, the elbow most commonly rests in a flexed position. Patients may present with a combination of muscle spasticity, myostatic contracture, and/or joint contracture. A focused history and physical examination are essential for developing individualized surgical plans that account for variations in deformity severity and patient goals. Patients may present with or without volitional control; goals and treatment options differ depending on the degree of control present. Techniques include hyperselective neurectomy, tendon lengthening, muscle origin release, myotomy, tenotomy, periarticular soft tissue release, and skin rearrangement. This article presents a comprehensive review of the surgical approach to the volitional and nonvolitional spastic elbow deformities.
This is a behavioral intervention whereby participants write (Value Affirmation and Future Selves Combination) for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
Patients receive atezolizumab IV over 60 minutes and 14-19 days later, undergo surgical resection. Following surgery patients may receive atezolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo MRI at baseline, 24-72 hours after surgery, then every 9 weeks until progression and blood sample collection throughout the study.
Fetal growth restriction (FGR) increases cardiovascular risk by cardiac remodeling and programming. This systematic review and meta-analysis across species examines the use of echocardiography in FGR offspring at different ages. PubMed and Embase.com were searched for animal and human studies reporting on echocardiographic parameters in placental insufficiency-induced FGR offspring. We included six animal and 49 human studies. Although unable to perform a meta-analysis of animal studies because of insufficient number of studies per individual outcome, all studies showed left ventricular dysfunction. Our meta-analyses of human studies revealed a reduced left ventricular mass, interventricular septum thickness, mitral annular peak velocity, and mitral lateral early diastolic velocity at neonatal age. No echocardiographic differences during childhood were observed, although the small age range and number of studies limited these analyses. Only two studies at adult age were performed. Meta-regression on other influential factors was not possible due to underreporting. The few studies on myocardial strain analysis showed small changes in global longitudinal strain in FGR offspring. The quality of the human studies was considered low and the risk of bias in animal studies was mostly unclear. Echocardiography may offer a noninvasive tool to detect early signs of cardiovascular predisposition following FGR. Clinical implementation yet faces multiple challenges including identification of the most optimal timing and the exact relation to long-term cardiovascular function in which echocardiography alone might be limited to reflect a child's vascular status. Future research should focus on myocardial strain analysis and the combination of other (non)imaging techniques for an improved risk estimation.NEW & NOTEWORTHY Our meta-analysis revealed echocardiographic differences between fetal growth-restricted and control offspring in humans during the neonatal period: a reduced left ventricular mass and interventricular septum thickness, reduced mitral annular peak velocity, and mitral lateral early diastolic velocity. We were unable to pool echocardiographic parameters in animal studies and human adults because of an insufficient number of studies per individual outcome. The few studies on myocardial strain analysis showed small preclinical changes in FGR offspring.
Detection of the pathogen in blood cultures as soon as possible reduces mortality significantly by providing timely initiation of treatment1. However, when skin antisepsis is not performed properly, an increase in the rate of contamination is observed. In this study, it was planned to compare the contamination rate of two antiseptics, povidine iodine/alcohol and Chlorhexidine/alcohol used as skin antisepsis, in the blood culture taken.

Full randomization" will be applied in the study. Multiples of 3 of the patients to be included in the study will be included in the "Chloraprep" group, the remaining patients and multiples of 2 will be included in the "povidine/iodine" group. . According to the number of samples determined for each institution, patients who came to the outpatient clinic during data collection and accepted to participate in the study will be randomly selected.